Immunosuppressants
are medicines or drugs that lower the ability of the body to reject a
transplanted organ. They are also known as anti-rejection drugs.
Various
factors are propelling the immunosuppressive
drugs market
growth. These factors, as per the new Market Research Future report, include
the growing rate of autoimmune diseases, growing need for organ
transplantation, increasing rates of organ failure, increasing use of tissue
engineering in organ transplant, and burgeoning demand for organ
replacement.
On
the flip side, stem cell therapy used as an alternative to organ
transplantation, lack of awareness regarding immunosuppressive drugs, shortage
of donors for organ transplant, high drug cost, and uncertainty of the action
of these drugs on complex organ transplantations are factors that may deter the
immunosuppressive drugs market growth over the forecast period.
Key Players
Notable
players profiled in the immunosuppressive drugs market report include Zydus
Cadila (India), Actavis, Inc. (US), Pfizer Inc. (US), Novartis AG
(Switzerland), Mylan Laboratories Inc. (US), Glenmark Pharmaceuticals, Inc
(India), Bristol-Myers Squibb Company (US), GlaxoSmithKline PLC (UK), Genzyme
Co. (US), F. Hoffmann-La Roche AG (Switzerland), Astellas Pharma (Japan), and
Accord Healthcare (US).
Industry News
October
2019: Lupin has introduced Mycophenolate Mofetil Capsules USP, a generic
version of Roche’s CellCept. These are antimetabolite immunosuppressant that is
indicated for prophylaxis of organ rejections in liver transplant, kidney
transplant, and allogenic kidney recipients and must be used together with
other forms of immune suppressants.
For
More Information Visit @ https://www.marketresearchfuture.com/reports/capsule-endoscopy-market-1359
No comments:
Post a Comment